Primary Anti-Phospholipid Antibody Syndrome: Real-World Defining Features of Rethrombosis in the Course of Disease
Table 2
Demographic, clinical, and laboratory parameters and risk profile at onset and end of follow-up, according to the occurrence or not of repeated thrombotic events in patients under anticoagulation, presence of the characteristic versus absence of the characteristic (%).
Characteristic
Total patients with the characteristic, (%)
Patients with repeated thrombotic events under anticoagulation (), presence of the characteristic vs. absence of the characteristic (%)
Male
17 (31)
29 vs. 13.5
Caucasian
50 (93)
20 vs. 0
Risk factors at the time of APS diagnosis:
Hypertension
23 (43)
13 vs. 22.5
Dyslipidaemia
21 (39)
28.5 vs. 12
Active smoking
21 (39)
19 vs. 18
Type 2 diabetes mellitus
6 (11)
17 vs. 19
Hormonal contraception
10 (18.5)
0 vs. 23
Obesity
14 (26)
29 vs. 15
Immobility
5 (9)
0 vs. 10
Perioperative
1 (2)
0 vs. 19
aGAPSS ≥8, (%)
40 (74)
20 vs. 14
At onset:
Anticardiolipin IgM positive
14 (26)
29 vs. 15
Anticardiolipin IgG positive
26 (48)
31 vs. 7
Anti-β(2)GPI IgM positive
15 (28)
33 vs. 13
Anti-β(2)GPI IgG positive
26 (48)
27 vs. 11
Lupus anticoagulant positive
50 (93)
20 vs. 0
Lupus anticoagulant alone positive
18 (33)
11 vs. 18
LA and all other aPL
9 (17)
44 vs. 13
High-risk profile at onset, (%)
49 (91)
20 vs. 0
At end of follow-up:
Anticardiolipin IgM positive
7 (13)
28 vs. 17
Anticardiolipin IgG positive
22 (41)
32 vs. 9
Anti-β(2)GPI IgM positive
4 (7)
75 vs. 14
Anti-β(2)GPI IgG positive
20 (37)
35 vs. 9
Lupus anticoagulant positive
30 (55)
27 vs. 8
Lupus anticoagulant alone positive
13 (24)
8 vs. 22
LA and all other aPL
3 (5.5)
67 vs. 2
High-risk profile, (%)
31 (57)
26 vs. 9
Sustained high-risk profile status, (%)
31 (57)
26 vs. 9
Nonreversion to negative status (aPL and LA), (%)
41 (76)
19.5 vs. 16
Ratio of RTE patients positive for a characteristic over the number of patients in the cohort with that characteristic versus (vs.) ratio of RTE patients without that characteristic over the number of characteristic negative patients in the cohort.
